The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Milestone Pharmaceuticals P/E ratio is -5.76. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Milestone Pharmaceuticals’s P/E ratio

What is Milestone Pharmaceuticals P/E Ratio?

Milestone Pharmaceuticals’ P/E ratio is -5.76, which represents a 107.74% decrease from the same period last year. their average P/E ratio is 11.1 and their 5-year average is 1.34.

What is Milestone Pharmaceuticals Net EPS?

the net EPS of Milestone Pharmaceuticals for the most recent quarter was -1.05 dollars, which represents a 8.25% decrease from the same period last year.

Who are Milestone Pharmaceuticals Competitors?

Based on Jika.io AI model, Quantum Genomics Société Anonyme, Ardelyx, Clearside Biomedical, Concert Pharmaceuticals, Citius Pharmaceuticals, Eiger BioPharmaceuticals, La Jolla Pharmaceutical, Rezolute are considered to be Milestone Pharmaceuticals’s competitors because the companies operate within the same industry as Milestone Pharmaceuticals and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Milestone Pharmaceuticals.

Who is Milestone Pharmaceuticals’s Biggest competitor?

Milestone Pharmaceuticals’ biggest competitor is Quantum Genomics Société Anonyme, based on the Jika.io AI model. it has a similar market capitalization to Milestone Pharmaceuticals within the industry, it dominates a similar share of the market as Milestone Pharmaceuticals, and it provides and markets very similar services.

What industry is Milestone Pharmaceuticals in?

Milestone Pharmaceuticals is part of the biotechnology and healthcare industry.

Milestone Pharmaceuticals vs Quantum Genomics Société Anonyme

Market Cap: Milestone Pharmaceuticals’s Market Cap of 181036576 is higher than Quantum Genomics Société Anonyme Market Cap of 51722632.
Average Volume: Milestone Pharmaceuticals’s Average Volume of 59930.0 is higher than Quantum Genomics Société Anonyme Average Volume of 124506.0.
Beta: Milestone Pharmaceuticals’s Beta of 3.15 is higher than Quantum Genomics Société Anonyme Beta of 0.99.
Revenue: Milestone Pharmaceuticals’s Revenue of 15.0M is higher than Quantum Genomics Société Anonyme Revenue of 116211.0.
Net Income: Milestone Pharmaceuticals’s Net Income of -42.853M is higher than Quantum Genomics Société Anonyme Net Income of -16.556M.
Gross Profit: Milestone Pharmaceuticals’s Gross Profit of 15.0M is higher than Quantum Genomics Société Anonyme Gross Profit of -1.631M.
Ebitda: Milestone Pharmaceuticals’s Ebitda of -42.54M is higher than Quantum Genomics Société Anonyme Ebitda of -18.939M.
P/E Ratio: Milestone Pharmaceuticals’s P/E Ratio of -5.76 is higher than Quantum Genomics Société Anonyme P/E Ratio of -3.48.
P/B Ratio: Milestone Pharmaceuticals’s P/B Ratio of 2.54 is lower than Quantum Genomics Société Anonyme P/B Ratio of 2.95.
P/FCF Ratio: Milestone Pharmaceuticals’s P/FCF Ratio of -7.36 is higher than Quantum Genomics Société Anonyme P/FCF Ratio of -3.16.
ROE: Milestone Pharmaceuticals’s ROE of -0.37 is lower than Quantum Genomics Société Anonyme ROE of -0.54.
ROA: Milestone Pharmaceuticals’s ROA of -0.42 is lower than Quantum Genomics Société Anonyme ROA of -0.43.
Return On Capital Employed: Milestone Pharmaceuticals’s Return On Capital Employed of -0.44 is lower than Quantum Genomics Société Anonyme Return On Capital Employed of -0.76.
Assets (Total): Milestone Pharmaceuticals’s Assets (Total) of 119.849M is lower than Quantum Genomics Société Anonyme Assets (Total) of 22.586M.
Debt (Total): Milestone Pharmaceuticals’s Debt (Total) of 698000.0 is higher than Quantum Genomics Société Anonyme Debt (Total) of 3.003M.

Milestone Pharmaceuticals vs Ardelyx

Market Cap: Milestone Pharmaceuticals’s Market Cap of 181036576 is higher than Ardelyx Market Cap of 90143016.
Average Volume: Milestone Pharmaceuticals’s Average Volume of 59930.0 is higher than Ardelyx Average Volume of 3.401M.
Beta: Milestone Pharmaceuticals’s Beta of 3.15 is higher than Ardelyx Beta of 1.85.
Revenue: Milestone Pharmaceuticals’s Revenue of 15.0M is higher than Ardelyx Revenue of 10.097M.
Net Income: Milestone Pharmaceuticals’s Net Income of -42.853M is higher than Ardelyx Net Income of -158.165M.
Gross Profit: Milestone Pharmaceuticals’s Gross Profit of 15.0M is lower than Ardelyx Gross Profit of 9.097M.
Ebitda: Milestone Pharmaceuticals’s Ebitda of -42.54M is higher than Ardelyx Ebitda of -152.218M.
P/E Ratio: Milestone Pharmaceuticals’s P/E Ratio of -5.76 is higher than Ardelyx P/E Ratio of -0.53.
P/S Ratio: Milestone Pharmaceuticals’s P/S Ratio of 8.52 is higher than Ardelyx P/S Ratio of 20.49.
P/B Ratio: Milestone Pharmaceuticals’s P/B Ratio of 2.54 is higher than Ardelyx P/B Ratio of 1.27.
P/FCF Ratio: Milestone Pharmaceuticals’s P/FCF Ratio of -7.36 is higher than Ardelyx P/FCF Ratio of -0.6.
ROE: Milestone Pharmaceuticals’s ROE of -0.37 is lower than Ardelyx ROE of -1.77.
ROA: Milestone Pharmaceuticals’s ROA of -0.42 is lower than Ardelyx ROA of -1.18.
Return On Capital Employed: Milestone Pharmaceuticals’s Return On Capital Employed of -0.44 is lower than Ardelyx Return On Capital Employed of -1.84.
Gross Profit Margin: Milestone Pharmaceuticals’s Gross Profit Margin of 0.5 is lower than Ardelyx Gross Profit Margin of 0.98.
Assets (Total): Milestone Pharmaceuticals’s Assets (Total) of 119.849M is lower than Ardelyx Assets (Total) of 149.913M.
Debt (Total): Milestone Pharmaceuticals’s Debt (Total) of 698000.0 is higher than Ardelyx Debt (Total) of 45.504M.
Shareholders Equity: Milestone Pharmaceuticals’s Shareholders Equity of 112.6M is lower than Ardelyx Shareholders Equity of 82.617M.

Milestone Pharmaceuticals vs Clearside Biomedical

Market Cap: Milestone Pharmaceuticals’s Market Cap of 181036576 is higher than Clearside Biomedical Market Cap of 84812064.
Average Volume: Milestone Pharmaceuticals’s Average Volume of 59930.0 is higher than Clearside Biomedical Average Volume of 235541.0.
Beta: Milestone Pharmaceuticals’s Beta of 3.15 is higher than Clearside Biomedical Beta of 2.18.
Revenue: Milestone Pharmaceuticals’s Revenue of 15.0M is lower than Clearside Biomedical Revenue of 29.575M.
Net Income: Milestone Pharmaceuticals’s Net Income of -42.853M is lower than Clearside Biomedical Net Income of 376000.0.
Gross Profit: Milestone Pharmaceuticals’s Gross Profit of 15.0M is lower than Clearside Biomedical Gross Profit of 29.575M.
Ebitda: Milestone Pharmaceuticals’s Ebitda of -42.54M is lower than Clearside Biomedical Ebitda of 554000.0.
P/E Ratio: Milestone Pharmaceuticals’s P/E Ratio of -5.76 is lower than Clearside Biomedical P/E Ratio of 141.0.
P/S Ratio: Milestone Pharmaceuticals’s P/S Ratio of 8.52 is higher than Clearside Biomedical P/S Ratio of 3.26.
P/B Ratio: Milestone Pharmaceuticals’s P/B Ratio of 2.54 is lower than Clearside Biomedical P/B Ratio of 2.67.
P/FCF Ratio: Milestone Pharmaceuticals’s P/FCF Ratio of -7.36 is higher than Clearside Biomedical P/FCF Ratio of -65.0.
ROE: Milestone Pharmaceuticals’s ROE of -0.37 is lower than Clearside Biomedical ROE of 0.0.
ROA: Milestone Pharmaceuticals’s ROA of -0.42 is lower than Clearside Biomedical ROA of 0.0.
Return On Capital Employed: Milestone Pharmaceuticals’s Return On Capital Employed of -0.44 is lower than Clearside Biomedical Return On Capital Employed of 0.0.
Gross Profit Margin: Milestone Pharmaceuticals’s Gross Profit Margin of 0.5 is lower than Clearside Biomedical Gross Profit Margin of 0.84.
Assets (Total): Milestone Pharmaceuticals’s Assets (Total) of 119.849M is lower than Clearside Biomedical Assets (Total) of 42.903M.
Debt (Total): Milestone Pharmaceuticals’s Debt (Total) of 698000.0 is higher than Clearside Biomedical Debt (Total) of 675000.0.

Milestone Pharmaceuticals vs Concert Pharmaceuticals

Market Cap: Milestone Pharmaceuticals’s Market Cap of 181036576 is lower than Concert Pharmaceuticals Market Cap of 205788112.
Average Volume: Milestone Pharmaceuticals’s Average Volume of 59930.0 is lower than Concert Pharmaceuticals Average Volume of 831701.0.
Beta: Milestone Pharmaceuticals’s Beta of 3.15 is higher than Concert Pharmaceuticals Beta of 0.31.
Revenue: Milestone Pharmaceuticals’s Revenue of 15.0M is lower than Concert Pharmaceuticals Revenue of 32578.0.
Net Income: Milestone Pharmaceuticals’s Net Income of -42.853M is lower than Concert Pharmaceuticals Net Income of -80051.0.
Gross Profit: Milestone Pharmaceuticals’s Gross Profit of 15.0M is higher than Concert Pharmaceuticals Gross Profit of 0.0.
Ebitda: Milestone Pharmaceuticals’s Ebitda of -42.54M is lower than Concert Pharmaceuticals Ebitda of 1.399M.
P/E Ratio: Milestone Pharmaceuticals’s P/E Ratio of -5.76 is higher than Concert Pharmaceuticals P/E Ratio of -4.47.
P/S Ratio: Milestone Pharmaceuticals’s P/S Ratio of 8.52 is higher than Concert Pharmaceuticals P/S Ratio of 4.99.
P/B Ratio: Milestone Pharmaceuticals’s P/B Ratio of 2.54 is higher than Concert Pharmaceuticals P/B Ratio of 2.12.
P/FCF Ratio: Milestone Pharmaceuticals’s P/FCF Ratio of -7.36 is higher than Concert Pharmaceuticals P/FCF Ratio of -2.43.
ROE: Milestone Pharmaceuticals’s ROE of -0.37 is higher than Concert Pharmaceuticals ROE of -0.35.
ROA: Milestone Pharmaceuticals’s ROA of -0.42 is higher than Concert Pharmaceuticals ROA of -0.28.
Return On Capital Employed: Milestone Pharmaceuticals’s Return On Capital Employed of -0.44 is lower than Concert Pharmaceuticals Return On Capital Employed of -0.78.
Gross Profit Margin: Milestone Pharmaceuticals’s Gross Profit Margin of 0.5 is higher than Concert Pharmaceuticals Gross Profit Margin of 0.0.
Assets (Total): Milestone Pharmaceuticals’s Assets (Total) of 119.849M is lower than Concert Pharmaceuticals Assets (Total) of 165.316M.
Debt (Total): Milestone Pharmaceuticals’s Debt (Total) of 698000.0 is higher than Concert Pharmaceuticals Debt (Total) of 1.155M.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. the company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. it has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil for prophylactic and therapeutic use in humans. the company was established in 2003 and is based in Montréal, Canada.

 

https://www.articlering.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here